Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 221.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Data is available to registered users only
Target Price
The average target price of 6160.HK is 216 and suggests 1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Data is available to registered users only
Buy
Sell